Therapies used to control symptoms related to the release of mast-cell mediators in ISM patients grouped according to the sBT slope (<0.15 vs. ≥0.15) after 48 months of follow-up.

临床疗效比较

Results are expressed as number of cases and percentage between brackets. No statistically significant differences (p >0.05) were found between groups. *Scheduled disodium cromolyn plus scheduled non-

NIAID Data Ecosystem50

Supplementary figures for Cladribine (2-CdA) improves cutaneous manifestations, DLQI and MC-QoL of patients with mastocytosis

肥大细胞增多症治疗

皮肤病

This set of supplementary figures illustrates additional content of the article "Cladribine (2-CdA) improves cutaneous manifestations, DLQI and MC-QoL of patients with mastocytosis"

Mendeley Data10

Supplementary Material for: Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study)

肥大细胞增多症治疗

奥马珠单抗疗效

Background: Patients with mastocytosis often suffer from a variety of symptoms caused by mast cell mediators where treatments remain difficult, showing various success rates. Omalizumab, a monoclonal

Figshare2020-01-20 更新00

Supplementary figures for Cladribine (2-CdA) improves cutaneous manifestations, DLQI and MC-QoL of patients with mastocytosis

资源简介：

相关数据集